Novo Nordisk potentially facing tough competition from Amgen's obesity candidate
Amgen’s AMG 113 is still in the early stages of development, but is already shaping up to be a worthy competitor to Novo Nordisk’s Wegovy, says Handelsbanken.
by marketwire, translated by daniel pedersen
Novo Nordisk obesity treatment, Wegovy, risks running into a tough competition from a new drug candidate developed by US-based Amgen, Swedish bank Handelsbanken assesses.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma CEO has high hopes for obesity candidate
For subscribers
Novo Nordisk shot helps teens lose weight, new study finds
For subscribers
